Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.95 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736635 | 0.97 | GAA (1.00) | GAANPSR1LMNATHRBPOLB | |
| Hydrochloric Acid SCHEMBL29127785 | 0.84 | GAA (0.68) | GAANPSR1LMNATHRBPOLB | |
| SCHEMBL6466244 | 0.77 | GAA (0.65) | GAANPSR1LMNATHRBPOLB | |
| SCHEMBL18207941 | 0.72 | GAA (0.58) | GAATSHR | |
| SCHEMBL2825473 | 0.70 | GAA (0.56) | GAANPSR1LMNATHRBPOLB | |
| Phosphoric Acid SCHEMBL27509750 | 0.70 | GAA (0.56) | GAANPSR1LMNATHRBPOLB | |
| SCHEMBL1092162 | 0.70 | GAA (0.56) | GAANPSR1LMNATHRBPOLB | |
| SCHEMBL1091418 | 0.70 | GAA (0.56) | GAANPSR1LMNATHRBPOLB | |
| Phosphoric Acid SCHEMBL21408297 | 0.70 | GAA (0.56) | GAANPSR1LMNATHRBPOLB | |
| Hydrochloric Acid SCHEMBL28398363 | 0.67 | GAA (0.46) | GAANPSR1LMNATHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243549-B1 | A CATALYST SYSTEM | LUCITE INT UK LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-9802185-B2 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20150321186-A1 | CATALYST SYSTEM | Mitsubishi Chemical UK Limited (GB) | 2015-11-12 | — | — | US | disclosed |
| EP-2243548-B1 | A CATALYST SYSTEM | LUCITE INT UK LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-9040445-B2 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| EP-1713582-B1 | A CATALYST SYSTEM | LUCITE INT UK LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| EP-1554039-B1 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINO)METALLOCENE LIGAND | LUCITE INT UK LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2243549-A1 | A catalyst system | Lucite International UK Limited (GB) | 2010-10-27 | — | — | EP | disclosed |
| EP-2243548-A1 | A catalyst system | Lucite International UK Limited (GB) | 2010-10-27 | — | — | EP | disclosed |
| EP-1534427-B1 | AN ADAMANTYL CATALYST SYSTEM | LUCITE INT UK LTD (GB) | 2009-10-21 | — | — | EP | disclosed |
| US-7371705-B2 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| US-20070282124-A1 | Catalyst System | LUCENT INTERNATIONAL UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20060252935-A1 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1713582-A1 | A CATALYST SYSTEM | Lucite International UK Limited (GB) | 2006-10-25 | — | — | EP | disclosed |
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-05-18 | — | — | US | disclosed |
| WO-2005079981-A1 | A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1554039-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL)FERROCENE LIGAND | Lucite International UK Limited (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1534427-A1 | AN ADAMANTYL CATALYTIC SYSTEM | Lucite International UK Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004024322-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL) FERROCENE LIGAND | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004014552-A1 | A PHOSPHA-ADAMANTANE (S) CATALYTIC SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | ADORA2A, ADORA3, ADGRE5 | GAA 3243/4885GRIN2D 567/4885GRIN3B 522/4885 |
| US-20060252935-A1 | Catalyst system | ELOB, SOD1, ESR1 | GAA 1618/4885GRIN2D 1910/4885GRIN3B 729/4885 |
| US-20150321186-A1 | CATALYST SYSTEM | SMS, COASY, ABCB7 | GAA 3561/4885GRIN2D 3265/4885GRIN3B 1989/4885 |
| US-20070282124-A1 | Catalyst System | SMS, COASY, ABCB7 | GAA 3561/4885GRIN2D 3265/4885GRIN3B 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.